latest news in companies
DeepSeek Set to Challenge US Rivals with New Coding AI in February
Hangzhou, Saturday, 10 January 2026.
Arriving mid-February, DeepSeek’s V4 reportedly outperforms OpenAI and Anthropic in internal coding benchmarks, marking a significant breakthrough in handling complex, extensive software development prompts.
Bethesda’s Six Million Dollar Bid Crushed Original Creators’ Hopes to Reclaim Fallout
Rockville, Saturday, 10 January 2026.
Original developers secured funding to repurchase Fallout, yet never made an offer; Bethesda’s aggressive $6 million valuation rendered competing bids irrelevant, cementing the franchise’s multi-billion dollar trajectory.
Pony AI and Gilead Sciences Drive Early 2026 Nasdaq Momentum
New York, Saturday, 10 January 2026.
Trading data reveals a surge in interest for Pony AI following its January 9 partnership expansion to deploy over 600 robotaxis, highlighting a market shift toward tangible autonomous technology and biopharma stability.
Netflix Breaks Tradition with Performance Bonuses for Affleck and Damon’s ‘The Rip’
Los Angeles, Saturday, 10 January 2026.
In a significant departure from its standard upfront payment model, Netflix has agreed to performance-based bonuses for all 1,200 crew members of the upcoming film “The Rip.” This strategic pivot, negotiated by Ben Affleck and Matt Damon, aligns compensation directly with viewership success.
Jim Cramer Rejects Nike Downgrade as Insider Buying Signals Turnaround
New York, Saturday, 10 January 2026.
CNBC’s Jim Cramer labeled a recent Nike downgrade “fatuous,” arguing that significant insider purchases by CEO Elliott Hill and Apple’s Tim Cook signal a genuine business turnaround despite analyst skepticism.
Johnson & Johnson Agrees to Lower Drug Prices in Exchange for Tariff Exemptions
New Brunswick, Saturday, 10 January 2026.
Securing crucial tariff exemptions, Johnson & Johnson agrees to slash U.S. drug prices to match international rates, becoming the latest industry giant to join the administration’s TrumpRx.gov initiative.
Corcept Therapeutics Faces Market Selloff and Legal Probes Following FDA Rejection of Relacorilant
San Francisco, Friday, 9 January 2026.
Corcept Therapeutics (NASDAQ: CORT) is under intense pressure after the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, a treatment for hypertension caused by hypercortisolism. The regulatory rejection, announced on December 31, 2025, precipitated a massive 50% collapse in share value, effectively erasing $3.6 billion in market capitalization. While the FDA acknowledged some positive trial data, it concluded that additional evidence is required to establish the drug’s effectiveness. Consequently, the company now faces a wave of investigations from shareholder rights law firms, including Hagens Berman and Scott+Scott. These inquiries focus on whether management overstated relacorilant’s clinical efficacy and the commercial prospects of its hypercortisolism business to investors. Analysts have subsequently downgraded price targets, casting doubt on Corcept’s ability to meet its projected revenue goals within the previously stated timeframe.